| Nov 12 |
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
|
| Nov 11 |
Climb Bio names Douglas Williams as chair
|
| Nov 11 |
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
|
| Oct 31 |
Climb Bio to Present at Upcoming Investor Conferences
|
| Oct 11 |
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
|
| Oct 2 |
Eliem Therapeutics Changes Name to Climb Bio
|
| Oct 2 |
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
|
| Sep 28 |
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m
|
| Sep 23 |
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
|
| Aug 14 |
Eliem Therapeutics GAAP EPS of -$1.81
|
